Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial

Background

Endovascular therapy is the standard of care for eligible patients with acute ischemic stroke due to LVO. However, nearly half of patients remain functionally dependent even after successful reperfusion. Albumin is a biologically plausible adjunctive cerebroprotective therapy and has shown neuroprotective effects in preclinical studies, but the clinical benefit of albumin combined with EVT remains uncertain.